FUJIFILM Diosynth Biotechnologies is advancing two large-scale biomanufacturing expansions. Lars Petersen, CEO and President, FUJIFILM Diosynth Biotechnologies, outlined the company’s biomanufacturing expansions plans at the DCAT Member Company Announcement Forum at DCAT Week.  

The company is proceeding with continued investment at its site in Hillerød, Denmark. The first investment of $928 million added six 20,000-L bioreactors, effectively doubling its commercial monoclonal antibody production capacity. This new capacity became operational in November 2024. An additional $1-6-billion expansion at the site is scheduled to be operational in 2026. 

The company is also expanding its site in Holly Springs, North Carolina, with an initial $2-billion investment in an end-to-end large-scale cell-culture biomanufacturing facility, which will include  eight 20,000-L bioreactors to be operational by the summar of 2025, and an additional $1.2-billion expansion for 8 x 20,000 L mammalian cell-culture bioreactors to be operational by 2028. The company is also investing in small-to-mid-scale capacity at its sites in Billingham, the UK, and Toyama, Japan.  

The company says it is aiming to quadruple its sales by $5 billion by fiscal year 2030 and is scaling its operations to meet the growing demand for advanced therapies, monoclonal antibodies and antibody-drug conjugates.